Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with…
- Trial name
- NCT06562543
- Testing
- Fruquintinib
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 78 people
- Sponsor
- Takeda
Metastatic Colorectal Cancer
Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate the clinical response and safety of CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type…
- Trial name
- CRC009 (NCT01550055)
- Testing
- CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009
- Volunteers
- 512 people
- Sponsor
- Shanghai Zhangjiang Biotechnology Limited Company
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Colorectal Neoplasms, Neoplasm Metastasis
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
To evaluate the survival benefit of pre-operation chemotherapy of primary tumor tesection (PTR) compared upfront PTR for colorectal cancer (CRC) patients with an asymptomatic resectable primary tumor and synchronous unresectable…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms, Chemotherapy; Maternal, Affecting Fetus
- Trial name
- NCT01307878
- Testing
- chemotherapy ± targeted therapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Fudan University
Ras-mutated Metastatic Colorectal Cancer
Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer
The primary aim of this study is to test whether the combination of valproic acid with bevacizumab and oxaliplatin/fluoropyrimidine regimens (mFOLFOX6/mOXXEL) can prolong progression free survival (PFS) as compared with…
- Trial name
- REVOLUTION (NCT04310176)
- Testing
- Bevacizumab, mFOLFOX6 regimen, mOXXEL regimen
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer.
- Trial name
- NCT00051688
- Testing
- tezacitabine, oxaliplatin
- Where
- 8 sites in United States
- Sponsor
- Chiron Corporation
Colorectal Cancer
A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
This is a randomized, open-label, active-control, multicenter trial comparing two oxaliplatin/Avastin-based treatment sequences as first-line therapy for metastatic colorectal cancer.
- Trial name
- NCT00114946
- Testing
- Avastin
- Volunteers
- 800 people
- Sponsor
- Genentech, Inc.
Breast Carcinoma, Colorectal Carcinoma
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic.
- Conditions
- Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast
- Trial name
- NCT03164486
- Testing
- 18F-αvβ6-BP
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Julie L. Sutcliffe, Ph.D
Colorectal Cancer
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the…
- Trial name
- NCT00118261
- Testing
- bevacizumab, erlotinib hydrochloride, fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Colorectal Cancer
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently…
- Trial name
- ELI (NCT05609656)
- Testing
- Irreversible electroporation, Calcium electroporation, Pembrolizumab
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Ismail Gögenur
Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
- Trial name
- BOND-4 (NCT07722754)
- Testing
- Cetuximab, Irinotecan, Bevacizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Guangdong Provincial People's Hospital
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Colorectal Cancer
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy such as irinotecan, capecitabine, leucovorin, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064181
- Testing
- FOLFIRI regimen, capecitabine, celecoxib
- Where
- 28 sites in Belgium, Egypt and 3 more
- Volunteers
- 86 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Colorectal Liver Metastases, Hepatocellular Carcinoma
Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression
The use of intraoperative ultrasound (IOUS) allows us to perform new conservative hepatectomies. The investigators previously reported the systematic subsegmentectomy by IOUS-guided finger compression for segments 2-3, which is…
- Conditions
- Colorectal Liver Metastases, Hepatocellular Carcinoma, Liver Malignancies
- Trial name
- NCT00797251
- Testing
- Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- University of Milan
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
- Trial name
- NCT03290937
- Testing
- Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Metastases, Colorectal Neoplasms
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Primary Objective : Compare the risk of occurrence of Grade3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin between treatment group and placebo group.
- Conditions
- Metastases, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT00305188
- Testing
- Xaliproden (SR57746A), Oxaliplatin, 5-Fluorouracil
- Where
- 13 sites in United States, Argentina and 11 more
- Volunteers
- 879 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX…
- Trial name
- NCT00890305
- Testing
- CT-011, FOLFOX
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 171 people
- Sponsor
- Medivation, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.